Evolution Biotechnologies (www.evolutionbiotech.com), the company working to expand the use of biological control into medically important areas, today announced that its UK patent application, “Acaricides” (GB1513981.9), relating to biological controls for house dust mites has progressed to the international stage as PCT application PCT/GB2016/052455. The PCT filing incorporates both data from the previous successful feasibility study and also recent findings identifying a biological agent capable of targeting multiple mite species.
Dr. David Harper, Chief Officer of Evolution, said “we are delighted to be able to incorporate the recent and exciting findings from our HDM research group, headed by Senior Scientist Dr. Victor Brugman, into this PCT filing. This illustrates the real progress that Evolution is making in developing its novel approach to control house dust mites, with the potential to bring real benefit to the hundreds of millions of asthma sufferers around the world.”
About Evolution Biotechnologies
Evolution Biotechnologies (UK company 09473027 / US company 6050853) has been established to extend the application of biological control from its agricultural roots into areas of biomedical importance. The company’s initial targets have both significant unmet need and high market potential. The first stage of Evolution’s work will be based on the outcomes of a successful feasibility study on biological control of the house dust mite. The potential for developing a biological control for the bed bug will also be evaluated, along with the potential for additional targets.
About biological control
Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”. Biological control methodologies have been extensively used in the agricultural sector and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date.
This document contains certain forward-looking statements – i.e., statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.